104 related articles for article (PubMed ID: 12866297)
21. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
23. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
24. Markers of the uPA system and common prognostic factors in breast cancer.
Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F
Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278
[TBL] [Abstract][Full Text] [Related]
25. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
26. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
27. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
Hanrahan EO; Valero V; Gonzalez-Angulo AM; Hortobagyi GN
J Clin Oncol; 2006 May; 24(13):2113-22. PubMed ID: 16648513
[TBL] [Abstract][Full Text] [Related]
28. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A
Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807
[TBL] [Abstract][Full Text] [Related]
29. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
30. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and predictive factors revisited.
Hayes DF
Breast; 2005 Dec; 14(6):493-9. PubMed ID: 16239111
[TBL] [Abstract][Full Text] [Related]
32. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
[TBL] [Abstract][Full Text] [Related]
33. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
Dowsett M; Dunbier AK
Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
[TBL] [Abstract][Full Text] [Related]
34. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
35. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Speleman L; Kerrebijn JD; Look MP; Meeuwis CA; Foekens JA; Berns EM
Head Neck; 2007 Apr; 29(4):341-50. PubMed ID: 17163465
[TBL] [Abstract][Full Text] [Related]
37. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
Offersen BV; Riisbro R; Knoop A; Brünner N; Overgaard J;
Acta Oncol; 2007; 46(6):782-91. PubMed ID: 17653901
[TBL] [Abstract][Full Text] [Related]
38. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
[TBL] [Abstract][Full Text] [Related]
40. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].
Fodor J
Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
